Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Next Previous
Trial Profile

A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sipuleucel-T (Primary) ; Enzalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STRIDE
  • Sponsors Dendreon Corporation

    • Most Recent Events

    • 15 Feb 2020 Results assessing association of humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T treatment in two studies (STAMP and STRIDE), presented at the 2020 Genitourinary Cancers Symposium.
    • 13 Feb 2020 Results published in the Dendreon corporation media release
    • 13 Feb 2020 According to a Dendreon corporation media release, results from STAMP and STRIDE studies assessing the association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity were presented at the 2020 ASCO Genitourinary (GU) Cancers Symposium in San Francisco.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top